Merus announces publication on mechanism of action of petosemtamab

Merus (MRUS) N.V. announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor and Leucine-Rich G, in the scientific journal “Cancers”, a MDPI publication. “LGR5+ stem-cell-like cells within a tumor, are frequently reported to be a central contributor to cancer growth, treatment resistance, and recurrence in CRC and other solid tumors,” said Cecile Geuijen, Ph.D., Senior Vice President and Chief Scientific Officer. “This publication outlining the scientific rationale for petosemtamab, a bispecific targeting EGFR and LGR5, underpins the strong previously reported phase 2 interim clinical data in both 1L PD-L1+ r/m HNSCC in combination with pembrolizumab and as a single-agent in 2L+ r/m HNSCC.”